Suppr超能文献

三环类抗抑郁药与头痛:系统评价和荟萃分析。

Tricyclic antidepressants and headaches: systematic review and meta-analysis.

机构信息

General Medicine Division, Walter Reed Army Medical Center, Washington, DC, USA.

出版信息

BMJ. 2010 Oct 20;341:c5222. doi: 10.1136/bmj.c5222.

Abstract

OBJECTIVE

To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches.

DESIGN

Meta-analysis.

DATA SOURCES

Medline, Embase, the Cochrane Trials Registry, and PsycLIT. Studies reviewed Randomised trials of adults receiving tricyclics as only treatment for a minimum of four weeks.

DATA EXTRACTION

Frequency of headaches (number of headache attacks for migraine and number of days with headache for tension-type headaches), intensity of headache, and headache index.

RESULTS

37 studies met the inclusion criteria. Tricyclics significantly reduced the number of days with tension-type headache and number of headache attacks from migraine than placebo (average standardised mean difference -1.29, 95% confidence interval -2.18 to -0.39 and -0.70, -0.93 to -0.48) but not compared with selective serotonin reuptake inhibitors (-0.80, -2.63 to 0.02 and -0.20, -0.60 to 0.19). The effect of tricyclics increased with longer duration of treatment (β=-0.11, 95% confidence interval -0.63 to -0.15; P<0.0005). Tricyclics were also more likely to reduce the intensity of headaches by at least 50% than either placebo (tension-type: relative risk 1.41, 95% confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to 2.62) or selective serotonin reuptake inhibitors (1.73, 1.34 to 2.22 and 1.72, 1.15 to 2.55). Tricyclics were more likely to cause adverse effects than placebo (1.53, 95% confidence interval 1.11 to 2.12) and selective serotonin reuptake inhibitors (2.22, 1.52 to 3.32), including dry mouth (P<0.0005 for both), drowsiness (P<0.0005 for both), and weight gain (P<0.001 for both), but did not increase dropout rates (placebo: 1.22, 0.83 to 1.80, selective serotonin reuptake inhibitors: 1.16, 0.81 to 2.97).

CONCLUSIONS

Tricyclic antidepressants are effective in preventing migraine and tension-type headaches and are more effective than selective serotonin reuptake inhibitors, although with greater adverse effects. The effectiveness of tricyclics seems to increase over time.

摘要

目的

评估三环类抗抑郁药治疗偏头痛、紧张型和混合型头痛的疗效和相对不良反应。

设计

荟萃分析。

资料来源

Medline、Embase、Cochrane 临床试验注册中心和 PsycLIT。研究纳入接受三环类抗抑郁药作为唯一治疗至少 4 周的成年人的随机试验。

资料提取

头痛发作次数(偏头痛的头痛发作次数和紧张型头痛的头痛天数)、头痛强度和头痛指数。

结果

37 项研究符合纳入标准。三环类抗抑郁药与安慰剂相比,显著减少了紧张型头痛的天数和偏头痛的头痛发作次数(平均标准化均数差值-1.29,95%置信区间-2.18 至-0.39 和-0.70,-0.93 至-0.48),但与选择性 5-羟色胺再摄取抑制剂(SSRIs)相比无差异(-0.80,-2.63 至 0.02 和-0.20,-0.60 至 0.19)。三环类抗抑郁药的疗效随着治疗时间的延长而增加(β=-0.11,95%置信区间-0.63 至-0.15;P<0.0005)。三环类抗抑郁药也更有可能将头痛强度降低至少 50%,与安慰剂(紧张型:相对风险 1.41,95%置信区间 1.02 至 1.89;偏头痛:1.80,1.24 至 2.62)或选择性 5-羟色胺再摄取抑制剂(1.73,1.34 至 2.22 和 1.72,1.15 至 2.55)相比。三环类抗抑郁药比安慰剂(1.53,95%置信区间 1.11 至 2.12)和选择性 5-羟色胺再摄取抑制剂(2.22,1.52 至 3.32)更易引起不良反应,包括口干(两者均 P<0.0005)、嗜睡(两者均 P<0.0005)和体重增加(两者均 P<0.001),但不会增加停药率(安慰剂:1.22,0.83 至 1.80,选择性 5-羟色胺再摄取抑制剂:1.16,0.81 至 2.97)。

结论

三环类抗抑郁药在预防偏头痛和紧张型头痛方面有效,且比选择性 5-羟色胺再摄取抑制剂更有效,但不良反应更多。三环类抗抑郁药的疗效似乎随时间增加而增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7eb/4787652/c850fb44cc5a/jacj775726.f1_default.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验